Angiogenesis Inhibitors: all 4,430 studies that test it
Page 6 of 45. Open to participants first (542), then studies with results posted, then the rest; newest registration first within each.
- Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System LymphomaRecruitingNCT04481815Phase 2
- TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLLRecruitingNCT04453345Phase 2/3
- Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC RearrangementRecruitingNCT04432714Phase 1/2
- Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular LymphomaRecruitingNCT04404088Phase 2
- Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)RecruitingNCT04374305Phase 2
- Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab MaintenanceRecruitingNCT04332367Phase 2
- Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell LymphomaRecruitingNCT04329130Phase 2
- Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)RecruitingNCT04301076Phase 1
- Study of Recombinant Human Endostatin Combined with Temozolomide and Irinotecan in Recurrent GliomasRecruitingNCT04267978Phase 2
- Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune InfiltrateRecruitingNCT04262687Phase 2
- A Study of Low Dose Bevacizumab With Conventional Radiotherapy Alone in Diffuse Intrinsic Pontine GliomaRecruitingNCT04250064Phase 2
- Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/BevacizumabRecruitingNCT04224636Phase 2
- Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel CancersRecruitingNCT04205968Phase 2
- Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerRecruitingNCT04181060Phase 3
- A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)RecruitingNCT04129710Phase 2
- MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)RecruitingNCT04110301Phase 1/2
- Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)RecruitingNCT04040361Phase 2
- A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLLRecruitingNCT03980002Phase 2
- Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver CancerRecruitingNCT03942328Phase 1/2
- Losartan + Sunitinib in Treatment of OsteosarcomaRecruitingNCT03900793Phase 1
- Pan Tumor Rollover StudyRecruitingNCT03899155Phase 2
- Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLCRecruitingNCT03872661Phase 2
- Intravitreal Methotrexate and R2(Rituximab & Lenalidomide) Regimen in Newly-diagnosed Primary Vitreoretinal LymphomaRecruitingNCT03746223Phase 2
- R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's MacroglobulinemiaRecruitingNCT03697356Phase 2
- VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple MyelomaRecruitingNCT03641456Phase 2
- Postoperative Concurrent Chemoradiotherapy Combined With Endostar for High-risk Early Stage Cervical CancerRecruitingNCT03622827Phase 2
- Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell LymphomaRecruitingNCT03523975Phase 1/2
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingNCT03424005Phase 1/2
- Conversion From Unresectable To Resectable Metastatic Colorectal Cancer.RecruitingNCT03401294Phase 2
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingNCT03297606Phase 2
- Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell LymphomaRecruitingNCT03223610Phase 1/2
- A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) PatientsRecruitingNCT03110822Phase 1
- Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell LymphomaRecruitingNCT03011814Phase 1/2
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingNCT02693535Phase 2
- A CpG-methylation-based Assay for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant TreatmentNot yet recruitingNCT02688491Not applicable
- Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of RecurrenceRecruitingNCT02446431Early Phase 1
- Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma MultiformeRecruitingNCT02285959Phase 1
- Efficiency Study for Acute Radiation-induced and Chemotherapy-induced Pulmonary Fibrosis With BevasizumabRecruitingNCT01917877Phase 2
- Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AARecruitingNCT01269853Phase 1/2
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingNCT01042379Phase 2
- Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural OutcomeRecruitingNCT00346814Phase 2/3
- Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMMActive, not recruitingNCT07150104Phase 1/2Results posted
- Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMMActive, not recruitingNCT07150091Phase 1/2Results posted
- A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)Active, not recruitingNCT06491914Phase 3Results posted
- Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)Active, not recruitingNCT06390826Phase 2Results posted
- A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)CompletedNCT06190093Phase 3Results posted
- A Study to Evaluate the Usability of the SB11 PFS in Subjects With Wet AMD or Macular Oedema Secondary to RVOCompletedNCT06176963Phase 2Results posted
- Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)CompletedNCT05989126Phase 3Results posted
- Isa-Pom-Dex in Elderly/Frail Subjects With RRMMActive, not recruitingNCT05911321Phase 2Results posted
- ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal CancerTerminatedNCT05824559Phase 1Results posted
- A Study of Tafasitamab and Lenalidomide in People With Mantle Cell LymphomaTerminatedNCT05788289Phase 2Results posted
- Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCCTerminatedNCT05776875Phase 2Results posted
- Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian CancerCompletedNCT05751629Phase 2Results posted
- Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral TherapyTerminatedNCT05717400Phase 4Results posted
- A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)CompletedNCT05704725Phase 3Results posted
- Pharmacokinetic Study of Oral ALXN1840 in Japanese and Non-Japanese Adult Healthy ParticipantsCompletedNCT05641311Phase 1Results posted
- Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell LymphomaTerminatedNCT05626322Phase 1/2Results posted
- A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab Prefilled SyringeCompletedNCT05569148Phase 3Results posted
- A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell LymphomaCompletedNCT05564052Phase 2Results posted
- Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A MutationTerminatedNCT05523440Phase 2Results posted
- A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participants in India With Diabetic Macular EdemaCompletedNCT05511038Phase 4Results posted
- A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of TreatmentTerminatedNCT05473715Phase 4Results posted
- A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy AdultsCompletedNCT05319912Phase 1Results posted
- A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy AdultsCompletedNCT05319899Phase 1Results posted
- Study of Oral ALXN1840 at 2 Dose Strengths in Healthy AdultsCompletedNCT05303324Phase 1Results posted
- Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple MyelomaTerminatedNCT05288062Phase 2Results posted
- Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial KitCompletedNCT05282004Phase 3Results posted
- Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL PatientsActive, not recruitingNCT05222555Phase 1/2Results posted
- Clinical Study to Evaluate PRO-169 for Diabetic Macular EdemaCompletedNCT05217680Phase 3Results posted
- Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous SystemActive, not recruitingNCT05211336Phase 1Results posted
- Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled SyringeCompletedNCT05161806Phase 3Results posted
- MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple MyelomaTerminatedNCT05090566Phase 2Results posted
- Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric CancerTerminatedNCT05071053Phase 2Results posted
- Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson DiseaseTerminatedNCT05047523Phase 3Results posted
- Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple MyelomaCompletedNCT05032820Phase 2Results posted
- Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction CaCompletedNCT04921904Phase 1/2Results posted
- Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular DegenerationCompletedNCT04864834Phase 3Results posted
- Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma PatientsTerminatedNCT04843579Phase 2Results posted
- A Study of Atezolizumab and Bevacizumab in Hepatocellular CarcinomaCompletedNCT04829383Phase 2Results posted
- Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related ChangesActive, not recruitingNCT04802161Phase 2Results posted
- A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular DegenerationCompletedNCT04777201Phase 3Results posted
- Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT04753216Phase 2Results posted
- Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer PatientsCompletedNCT04737187Phase 3Results posted
- A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic TherapyTerminatedNCT04732286Phase 3Results posted
- Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF TreatmentTerminatedNCT04707625Phase 4Results posted
- A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple MyelomaTerminatedNCT04700176Phase 2Results posted
- A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract CancerCompletedNCT04677504Phase 2Results posted
- To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)Active, not recruitingNCT04661007Phase 1/2Results posted
- A Randomized Trial of Low-Dose Bevacizumab vs Laser for Type 1 ROPTerminatedNCT04634604Phase 3Results posted
- MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLCCompletedNCT04633564Phase 3Results posted
- Pembrolizumab Plus Ramucirumab in Metastatic Gastric CancerCompletedNCT04632459Phase 2Results posted
- Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX Following Anti-VEGF Therapy in Neovascular AMDCompletedNCT04626128Phase 1/2Results posted
- Bioavailability Study of 2 Oral Formulations of ALXN1840CompletedNCT04610580Phase 1Results posted
- A Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Participants With Diabetic Macular Edema Treated With FaricimabCompletedNCT04597918Phase 2Results posted
- Copper Balance in Healthy Participants Administered ALXN1840CompletedNCT04594252Phase 1Results posted
- Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840CompletedNCT04573309Phase 2Results posted
- A Study of the Cardiac Effects of ALXN1840 in Healthy AdultsCompletedNCT04560816Phase 1Results posted
- A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced CancerTerminatedNCT04557384Phase 1Results posted
- Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)TerminatedNCT04541173Phase 2Results posted